compani
thought meet
execut solid pipeline/nilex sale street pt
host lli chairman/ceo svp/cso mtg w/ investor
focus diversifi volume-driven growth pipeline/nilex oppi
strh street diabet gain trulicity-rewind
taltz psa/ak
cross-ov trulic user lasmiditan/tanezumab filing/data ad
data nme drive growth focu cash
proce /dividend share repo reiter buy/pt
ep support dcf
execut solid ciali loe pipelin oppi under-valued
host lli chairman ceo evp/chief scientif offic cso
 director ir meet investor demand high
reiter volume-driven growth target enter one best
new product cycl sale form new product histori
grow ciali loe expand margin lli
global busi align four fastest grow therapeut area
diabet immunolog oncolog neurosci pain alzheim
rivet improv speed clinic develop time regulatori
filing/commerci look sustain flow innov rich
pipelin nme nilex opportun street
lli sale see exhibit support four new product launch
 bounti new indic line extens nilex opportun
enter attract market exhibit view posit drive
earn growth faster sale gross margin fix cost leverag yield
oper margin expans model model
sales/ep compound-annual-growth-rate vs street reiter
buy rais pt ep risk includ
biopharma group continu outperform last
month vs attract risk reward trade
discount index remain one favorit large-cap growth name
merck buy buy remain favorit name valu
 pharma buy smid-cap growth
tr target
compani
 product benefit faster clinic enrol
lli organ undergo transform wherebi reduc cycle-tim especi
phase clinic trial enrol highlight improv made speed clinic
trial enrol sinc day see note titl postview bullish thesi remain
intact target launch continu improv speed clinic trial
enrol highlight made improv year year human
dose launch due advanc analyt optim clinic trial patient enrol clinic
drug supply/ manufactur regulatori submiss olumi nda file took month
aim enhanc speed clinic develop evidenc quickli close
competit gap emgal migrain reiter track launch asset
per year annual rate look provid detail product
gain dec investor day
diabet product gain share rewind focal point
review push pull differ product across diabet franchis provid
us increas confid thesi track doubl diabet revenu
level lli trulic jardianc basaglar basal
insulin tradjenta growth offset declin short-act insulin humalog/
humulin gener view diabet market growth come outcomes-focus endpoint
weight loss reduc hospit cv benefit motiv pursu value-
base contract payer drive uptak product
trulic achiev leadership prescript us market overtak novo
nordisk novo-ch rate victoza market grow yoy accord august
prescript data iqvia trulic account market vs victoza
 ozemp inject becom standard care due superior
lower effect weight loss cv benefit complianc once-weekli dose base
diabet market model expect top us sale investor focus
whether trulic rewind data would show cv benefit best harm least limit downsid
risk anticip top-lin releas full data assum ada rewind less
sick popul see note longer trial durat highlight renal function data
notabl creatinin clearanc micro-albumin data correl cv risk lli rewind
evalu patient nvo cv outcom studi patient vs
longer year median follow-up vs primari endpoint rewind composit major
cardiovascular event mace compon includ cardiovascular death non-fat myocardi
infarct non-fat stroke optimist gener cv benefit best harm
least model trulic sale vs street
jardianc categori leader us share ahead johnson johnson
rate invokana market grow yoy rate expect jardianc heart
failur hf pivot trial emperor-reduc emperor-preserv show rapid signific
benefit primari cv endpoint potenti compel data could result earli stop
interim analysi lly/bi emperor trial focus long-term morbid mortal outcom
also optimist two initi pivot hf trial march measur potenti
benefit jardianc exercis capac heart failur emperi studi emperial-reduc
emperial-preserv measur chang exercis capac via walk test primari
complet may emperi trial uniqu jardianc sinc novarti nv
rate conduct similar trial entresto competit front expect class
volum trend benefit astrazeneca azn-gb rate declar cv outcom data
farxiga model jardianc allianc revenu vs street
tradjenta boehring ingelheim bi privat tradjenta posit gain share stabl
market sinc drug dpp-iv class show posit cardiovascular cv
outcom carmelina studi conting data carolina cv outcom studi
expect lly/bi file tradjenta cv outcom data review late model
tradjenta allianc revenu vs street lli basaglar biosimilar sanofi
sni rate lantu insulin glargin secur us share expens nvo
tresiba/levemir sanofi lantu see note titl us biopharma sanofi read-across
page
compani
co-agonist diabet pipelin front expect share result gip/
co-agonist annual confer european associ studi
diabet easd oct berlin germani investor call present
thursday octob estimate expect initi program late
earli note high bar efficaci move molecul phase given
competit intens categori phase result met high bar recal lli criteria
pursu dual co-agonist once-weekli dose better efficaci weight loss vs once-weekli
like trulic ozemp bullish lli co-agonist program
anoth underappreci diabet asset franchis intranas glucagon
submit fda/ema announc earn call juli two
competit asset horizon glucagon rescu auto-injector submit
fda august zealand pharma zeal rate like third market
complet phase trial rescu pen devic sept aim launch
view lli intranas glucagon well-posit first needle-fre rescu therapi
treatment hypoglycemia note deliveri mechan glucagon product requir
one spray nostril easier use inject glucagon one dose intranas
glucagon administ requir amount glucagon patient think portion
address hypoglycem market might requir train use competitor auto-injector devic
put advantag believ articul issu relat inject glucagon
nda file intranas formul auto-injector pen may price would
pariti current glucagon rescu pen expect price intranas glucagon
social respons price
diabet catalyst trulic rewind top-lin data jardianc hf studi interim analys
tradjenta carolina read-out co-agonist data easd oct potenti
approv intranas glucagon
immunolog sale street exh
lli in-lin immunolog product taltz/olumi numer growth avenu label
 geograph expans pipelin also deliv model
combin taltz/olumi sale street taltz gain share base
psoriasi pso market despit competit nv cosentyx jnj tremfya limit
use axspa reiter meet taltz nbrx share dermatolog derm
climb qoq also work diversifi taltz revenu psoriat arthriti
launch us/eu dec approv sbla file ankylos
spondyl axspa expect see note follow olumi jak approv
rheumatoid arthriti ra indic broad clinic develop effort expand label
anticip read-out pivot olumi studi atop dermat five breez studi
system lupu two brave studi respect also jump foray
initi adapt phase studi olumi treatment severe/
sever alopecia aeriata aa studi primari complet dec competitor
aa includ aclari rate concert rate compar
mechan action moa research publish natur medicin aa t-cell mediat
autoimmun diseas activ cytotox nkgd t-cell implic aa diseas
pathogenesi revers jak-inhibit anim mice model mechanist lli
inhibit immun journal indic inhibitor work
interferon gamma ifn- pathway inhibitor work interleukin il
mirikizumab lli pipelin includ mirikizumab inhibitor psoriasi
ulcer coliti crohn diseas share impress phase data mirikizumab
treatment psoriasi american academi dermatolog aad
mirikizumab show superior placebo achiev improv psoriasi area
sever pasi scale pasi respons mirikizumab treatment
arm measur vs placebo arm asset pipelin includ
page
compani
btk inhibitor rheumatoid arthriti least seven asset
bsab mab mab bsab pegyl inhibitor
immunolog catalyst taltz axspa sbla file olumi ad data present
acr oct chicago
investor highli interest emerg neuroscience/pain franchis add
fourth leg growth diabet immunolog oncolog lli pain franchis enter
commerci phase launch emgal galcanezumab late septemb lasmiditan
nda file clinic data long-term safeti data tanezumab
emgal galcanezumab receiv fda approv in-lin expect prophylaxi
treatment migrain chronic/ episod expect launch emgal parity-pric amgen
rate /novarti nv rate aimovig teva teva-il rate ajovi
month lli emgal highli differenti owe earli onset action load
dose benefit tough-to-treat episod cluster headach draw signific interest
neurologist lli emgal patient support program provid emgal month
patient commerci insur impli highli confid longer
use clinic data month vs month other conveni injector devic
use trulic taltz highlight road trulic prescrib also high
prescrib migrain therapi view aggress approach potenti enabl
secur market share posit class counter aggress sampl nvs/amgn
click compar aimovig/ajovi price discount commerci insur patient aimovig
avail co-pay maximum benefit cap unlik ajovi
co-pay alreadi secur posit chmp opinion emgal europ sept
ema final decis expect model lli emgal sale vs
also note district court massachusett dismiss teva litig case
vs patent infring contact strh sale person court
memorandum order motion dismiss
lasmiditan collect long-term safeti data gladiat conduct drug-drug
interact drive studi ahead nda file click jan deep dive
lasmiditan expect la us approv la sale street
lastli signific amount interest tanezumab view hold
lli anti-nerv growth factor ngf monoclon antibodi tanezumab high risk/high-reward
program tanezumab met three co-primari endpoint phase oa trial
remain three read-out earli key success tanezumab add high-margin
allianc revenu lli emerg pain franchis model heavili risk adjust sale
vs street
pain catalyst lasmiditan long-term safeti data gladiat enabl nda file
approv anticip tanezumab oa oa efficaci long-term
safeti chronic low back pain tango data earli emgal launch
verzenio abemaciclib demonstr earli success breast cancer
market track ahead novarti nv rate kisqali see upsid global verzenio
sale significantli street front line studi success along
growth product like cyramza lartruvo intrigu asset intern oncolog
pipelin howev oncolog area manag continu sourc extern innov
view base industri research global oncolog market expect grow
make oncolog must-win area opinion acknowledg
particip activ burgeon oncolog class immuno-oncology/parp
put disadvantag look sourc extern innov key tool close
page
compani
gap highlight two oncolog acquisit ytd aurka click note
armo click suggest take string pearl strategi oncolog although
look target launch asset china
oncolog catalyst verzenio ema final decis metastat
breast cancer set combo aromatas inhibitor fulvestr verzenio pegilodecakin anti-
data esmo oct munich washington dc addl busi
neuroscience/alzheim repres lli fifth leg growth
despit multipl high-profil setback continu invest alzheim franchis
next month anticip three phase read-out increas visibl
fifth leg growth pursu monoclon antibodi target
combin astrazeneca partnership asset bace inhibitor phase studi
trailblazer-alz treatment earli symptomat alzheim diseas estim
primari complet studi oct lli tau deposit monoclon antibodi
undergo phase studi earli symptomat ad patient primari complet januari
also pursu oral compound act dopamin receptor
enhanc treatment parkinson diseas dementia current enrol patient
trial presenc primari complet juli final announc
flortaucipir positron emiss tomographi pet imag agent met primari endpoint
phase studi predict brain tau patholog predict alzheim diseas diagnosi
plan detail flortaucipir result clinic trial alzheim diseas meet
ctad octob barcelona expect submit regulatori file flortaucipir
near-term carri meaning revenu asset model
neurosci pipelin becom de-risk clinic could see materi upward pressur our/
catalyst alzheim flortaucipir result ctad meet oct barcelona
three phase read-out next month
view china import growth platform
view china key part growth stori materi room grow wide varieti
product due larg patient pool rise healthcar expenditur note
pharmaceut sale china come multi-national compani impli larg untap
opportun larg diversifi pharma player invest china
chairman/ceo previous head china busi howev take cautious
optimist approach china acknowledg posit neg opportun
term key posit think improv effici china food drug
administr provid tailwind pharma growth countri cfda becom open
accept regulatori file base clinic data outsid china speed access
market cfda also process harmon guidelin global ich
council harmon technic requir pharmaceut human use
streamlin regulatori framework china gradual shift toward
exclus period intellectu properti would allay ip fear pharma
howev downsid price chines market often fraction us exampl
bristol-my squibb buy opdivo price china vs us
busi develop oncology/immunolog prioriti
lli elanco rate anim health ipo gener signific return first four day
trade ipo price vs total proce ipo
debt issuanc ad firepow lli ambit market cap stand
enterpris valu includ debt think divest lli stake
pursu tax-advantag manner would boost lli deal capac
end cash equival net debt/ebitda ratio think
could pursu acquisit without requir signific sharehold dilut indic
interest larg deal focus primarili earlier-stag pipelin opportun
rang lli ceo note meet look synergi driven mega-merg
page
compani
view lli capit alloc strategi focus pursu must-win oncolog
area immunolog segment follow growth dividend discuss next board
meet follow opportunist share repurchas author view lli two oncolog
acquisit ytd aurka armo type deal interest lli board
meet fall discuss dividend polici recal board author new
repo program time earn
page
compani
page
compani
exhibit lli select nme nilex opportun total address market size year launch
page
brand namegener namemechan actionind line extensiontot address market size launch yearemgalitygalcanezumabcalcitonin gene-rel peptid cgrp inhibitorprophylaxi treatment chronic/ episod receptor agonistacut growth factor ngf osteoarthr chronic lower back pain glucagonpeptid cv kinas jak inhibitoratop dermat baricitinibjanu kinas jak inhibitoralopecia areata kinas jak inhibitorsystem lupu erythematosu inhibitorpsoriat arthriti inhibitoraxi spondyloarthr axspa cotransport failur eli lilli compani
page
rang rang rang rang rang rang midpointstrh estimatesconsensu gross incomenot providednot providednot providednot providednot providednot incom rate incomenot providednot providednot providednot providednot providednot share countnot providednot providednot providednot providednot providednot flownot providednot providednot providednot providednot providednot yellow indic chang one-off guidanc updat sigilon deal compani
exhibit estim strh vs consensu
page
compound-annual-growth-rate vs strh vs vs compani
page
abemaciclib synjardi glyxambi insulin compani
page
galcanezumab strh- in-lin pipelin compani
exhibit incom statement
page
restat product incom non-oper incom incom interest incom net ep outstand analysisgross changenet product incom incom metricspric eli lilli compani
exhibit consolid balanc sheet
page
current plant equip borrow current portion lt tax current incom medic benefit non-curr paid-in benefit comprehens stock sharehold liabil sharehold eli lilli compani
exhibit statement
page
compens impair -- -- -- -- -- -- -- -- -- -- -- -- -- non-cash defer cash releas prop process common st borrow long-term long-term exchang begin end eli lilli compani
lilli lead research-bas biopharmaceut compani focus drug discoveri
clinic develop manufactur commerci pharmaceut product human
anim diseas gener sale yoy gener
us ex-u market human medicin busi includ core franchis
neurosci diabet women oncolog cardiovascular contribut
 total sale global leader diabet arena new product
trulic basaglar collabor asset jardianc tradjenta lli oncolog franchis
compris inhibitor verzenio abemaciclib alimta cyramza portrazza lartruvo
also place stake ground establish immunolog franchis
launch taltz olumi lli fourth leg emerg growth target pain market
three late-stag asset galcanezumab lasmiditan tanezumab enter one
best new product cycl year histori new product launch trulic jardianc
rate buy base attract low-teen earn growth mid-singl
digit volum driven sale growth commit expand oper margin tight
cost manag new product cycl unfold
model assum doubl diabet franchis level
jardianc basaglar trulic offset declin establish product
humalog humulin expect jardianc take materi share market older
gener therapi owe cardiovascular-benefit estim share shift
older gener therapi jardianc equat sale conting discount rebat
put upward pressur out-year estim also expect doubl
oncolog franchis base support verzenio alimta cyramza
portrazza lartruvo verzenio third-to-market inhibitor segment multipl use
breast cancer market alimta expect benefit combo use keytruda first-lin non-
small cell lung cancer nsclc alimta alreadi substanti presenc non-squam
nsclc market model assum maintain us exclus alimta
immunolog taltz olumi baricitinib expect contribut sale
think olumi long-term growth benefit expand asset commerci reach much
possibl geograph eu/japan label expans atop dermat system lupu
erythematosu psoriat arthriti taltz posit captur mid-teen percentag psoriasi
treat patient popul next five year lastli lli emerg pain franchis repres
fourth leg growth differenti late-stag asset significantli derisk emgal
lasmiditan tanezumab galcanezumab robust efficaci placebo-lik safeti posit take
materi share cgrp market lasmiditan first-in-class molecul offer
cardiovascular safeti advantag acut migrain standard-of-car triptan
oper leverag margin expans central thesi compani contain fix cost
grow revenu base next five year streamlin oper improv
cost structur posit achiev opex goal sale
valuat risk
pt assum trade ep reflect premium current
forward group averag forward price-to-earnings multipl think premium group averag
multipl justifi given lli diversifi volume-driven sale growth mid-singl digit sale
compound-annual-growth-rate oper leverag oper margin goe price
target support discount cash flow dcf intrins valu per share
risk thesi revolv around price commerci execut regulatori clinic risk
face upcom patent expir ciali alimta well recent
page
compani
expir patent strattera competit pressur trulic semaglutid humalog
biosimilar insulin lispro expect off-set four launch verzenio emgal
olumi lasmiditan
compani mention note
compani buy john bori
aclari rate
rate
astrazeneca azn rate
rate
elanco rate
johnson johnson rate
novarti nv rate
novo nordisk nvo-ch rate
sanofi sni rate
teva-il rate
zeal rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
